GlaxoSmithKline Pharmaceuticals Receives ₹222.23 Crore Tax Refund For FY 2022-23, Reports 37.8% YoY Net Profit Increase In Q1 2024

GlaxoSmithKline Pharmaceuticals Receives ₹222.23 Crore Tax Refund For FY 2022-23, Reports 37.8% YoY Net Profit Increase In Q1 2024

Global pharma giant GlaxoSmithKline Pharmaceuticals Ltd received an income tax refund of ₹222.23 crore for the assessment year 2022-23, following an order issued by the Income Tax Department on Tuesday.

FPJ News ServiceUpdated: Wednesday, September 04, 2024, 01:15 AM IST
article-image
GlaxoSmithKline gets tax refund of ₹222.23 crore | Representational Image

Global pharma giant GlaxoSmithKline Pharmaceuticals Ltd received an income tax refund of ₹222.23 crore for the assessment year 2022-23, following an order issued by the Income Tax Department on Tuesday.

Global healthcare major informed in regulatory filings of an Income Tax Order for Assessment Year 2022-23 issuing income tax refund of Rs 222.23 cr including interest.

GlaxoSmithKline Pharmaceuticals declared a 37.8% year-on-year (YoY) increase in net profit to Rs.182.3 crore in the first quarter ended June 30, 2024. GlaxoSmithKline’s net profit in the same quarter was Rs.132.3 crore while revenue rose by 7% to Rs.814.7 crore from Rs.761.7 crore in the same period last year

RECENT STORIES

Mumbai: Simone Tata, Stepmother Of Ratan Tata And Former Tata Group Director, In Critical Condition...

Mumbai: Simone Tata, Stepmother Of Ratan Tata And Former Tata Group Director, In Critical Condition...

Cabinet Approves Airport At Kota-Bundi In Rajasthan For ₹1,507 Crore

Cabinet Approves Airport At Kota-Bundi In Rajasthan For ₹1,507 Crore

Finance Minister Nirmala Sitharaman Likely To Place GST Rate Overhaul Proposal On August 20

Finance Minister Nirmala Sitharaman Likely To Place GST Rate Overhaul Proposal On August 20

Banks Sanction ₹62,791 Crore To 2.75 Lakh Beneficiaries Under Stand-Up India Scheme

Banks Sanction ₹62,791 Crore To 2.75 Lakh Beneficiaries Under Stand-Up India Scheme

US Tariffs Unlikely To Hurt India’s Long-Term Growth, Says S&P After Sovereign Rating Upgrade

US Tariffs Unlikely To Hurt India’s Long-Term Growth, Says S&P After Sovereign Rating Upgrade